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ABSTRACT 
Background: Treatment of prostate cancer with androgen deprivation therapy (ADT) is 
associated with metabolic changes that have been linked to an increase in cardiovascular 
risk. Methods: This randomised controlled trial investigated the effects of a 12-week lifestyle 
intervention that included supervised exercise training and dietary advice on markers of 
cardiovascular risk in 50 men on long-term ADT recruited to an on-going study investigating 
the effects of such a lifestyle intervention on quality of life. Participants were randomly 
allocated to receive the intervention or usual care. Cardiovascular outcomes included 
endothelial function (flow-mediated dilatation [FMD] of the brachial artery), blood pressure, 
body composition and serum lipids. Additional outcomes included treadmill walk time and 
exercise and dietary behaviours. Outcomes were assessed before randomisation [baseline], 
and 6, 12 and 24 weeks after randomisation. Results: At 12 weeks the difference in mean 
relative FMD was 2.2% (95% CI 0.1 to 4.3, p = 0.04) with an effect size of 0.60 (95% CI 
<0.01 to 1.18) favouring the intervention group. Improvements in skeletal muscle mass, 
treadmill walk time and exercise behaviour also occurred in the intervention group over that 
duration (p < 0.05). At 24 weeks, only the difference in treadmill walk time was maintained. 
Conclusion: This study demonstrates that lifestyle changes can improve endothelial 
function in men on long-term ADT for prostate cancer. The implications for cardiovascular 
health need further investigation in larger studies over longer duration. 
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INTRODUCTION 
Treatment with androgen deprivation therapy (ADT), has established benefits for men with 
locally advanced or metastatic prostate cancer [Schubert et al, 2012], but has been 
associated with the development of adverse events that can impact physical and mental 
well-being [Nguyen et al, 2015]. Evidence of metabolic complications of ADT that lead to 
increased cardiovascular risk is accumulating [Zhao et al, 2014]. Increased incidences of 
abdominal adiposity, insulin resistance, hyperglycaemia and hyperlipidaemia have been 
reported in men on such treatment [Nguyen et al, 2015].  
An increase in cardiovascular risk factors through the development of metabolic 
complications to long-term ADT has been supported by evidence of a reduction in flow-
mediated dilatation (FMD) of the brachial artery in men treated with long-term ADT [Gilbert et 
al, 2013]. Reduced FMD indicates endothelial dysfunction [Deanfield et al, 2007], which is 
regarded as an important early stage in the development of atherosclerosis [Celermajer, 
1997]. Endothelial function, as measured by brachial artery FMD, is also an established 
predictor of future cardiovascular events [Ras et al, 2013]. 
The traditional approach for presenting the results of FMD has been in the form of absolute 
change in arterial diameter after release of cuff occlusion or a simple ratio of the change of 
arterial diameter over the resting arterial diameter, so-called relative FMD [Edwards et al, 
2004, Gokce et al, 2002, Green et al, 2011]. Concerns have been expressed as to the 
appropriateness of simple ratio standards for such physiological variables, with allometric 
scaling being deemed to be both biologically and mathematically superior [Curran-Everett, 
2013, Packard and Boardman, 1999, Tanner, 1949]. More recently the validity of this 
approach has been demonstrated for FMD data [Atkinson et al, 2013, Atkinson and 
Batterham, 2013].  
Given the established benefits of exercise and dietary changes to cardiovascular health in 
other patient groups [Rippe and Angelopoulos, 2014], we hypothesised that a supervised 
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exercise training and dietary advice intervention would result in a reduction in cardiovascular 
risk factors in sedentary men on ADT. We tested this hypothesis in a randomised controlled 
trial and report the results herein. 
METHODS  
During the course of a randomised controlled trial investigating the effects of a lifestyle 
intervention on quality of life in men with prostate cancer on ADT (trial registration number 
ISRCTN88605738) a protocol amendment was approved by the Yorkshire and Humber NHS 
Research Ethics Committee to commence the collection of additional measures of 
cardiovascular risk.  
The patient population and intervention for the full trial have been described in detail 
previously [Bourke et al, 2014]. Here we present results for the subset of men recruited after 
the amendment was implemented.  
Sample size  
A sample size of 50 men was deemed sufficient to detect an absolute difference in relative 
brachial artery FMD of 2.6%; a difference reported in exercise studies in elderly patients at 
increased cardiovascular risk [Edwards et al, 2004, Gokce et al, 2002]. This sample size 
assumed a standard deviation (SD) of 3%, an alpha of 0.05, 80% power, and 10% attrition 
[Bourke et al, 2011]. 
Randomisation 
Participants were randomised 1:1 to receive 12 weeks of supervised exercise training and 
dietary advice in addition to usual care, or to receive usual care alone. A randomly ordered 
list of group allocation was generated at study commencement using the nQuery Statistical 
Software (nQuery Advisor 6.01, nQuery Statistical Solution, USA). Neither the researchers 
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nor the participants were informed of treatment allocation until completion of baseline 
assessments.  
Intervention and usual care 
Participants were prescribed three exercise sessions per week, tapering the supervision 
over the intervention (2:1 supervised to home-based in weeks 1-6 and 1:2 in weeks 7-12). 
An experienced exercise physiologist led supervised sessions that lasted approximately one 
hour and consisted of a mixture of aerobic, resistance and balance exercises. Aerobic 
exercise was 30 minutes at 55–75% of age-predicted maximum heart rate or 11–13 on the 
Borg Rating of Perceived Exertion (RPE) scale [Borg, 1982] using stationary cycles, rowing 
ergometers and treadmills. Resistance exercises were performed for 2-4 sets of 8-12 
repetitions beginning at an intensity of 60% of one repetition maximum and progressed 
through increasing volume before weight was increased. Advice on suitable exercises to 
perform at home for a minimum of 30 minutes was provided (e.g. brisk walking, cycling, and 
gym exercise). Participants were instructed how to monitor intensity using RPE. 
Small-group healthy-eating seminars led by the exercise physiologist, lasting approximately 
20 minutes, were delivered every two weeks throughout the intervention. Advice included: 
reduction in dietary fat intake to approximately 25% of total energy intake, consumption of at 
least five portions of fruit and vegetables each day, increased fibre consumption, decreased 
intake of refined carbohydrates, and limiting alcohol intake to 1-2 units per day. 
The control participants were men randomised to usual care who were followed up in the 
urology clinic as per usual clinical protocol. No restrictions were placed on them in relation to 
exercise or dietary behaviours over the period of the study.  
Outcome measures  
The primary outcome was brachial artery FMD (endothelium-dependent arterial dilatation) 
expressed as the percentage change in arterial diameter at 12 weeks. Secondary outcomes 
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include glyceryl trinitrate (GTN)-mediated brachial artery dilatation (endothelium-independent 
arterial dilatation), resting blood pressure, treadmill walk time, body mass and composition, 
lipid profile, biomarkers of disease status, physical activity and dietary behaviours. Outcome 
measures were assessed at baseline, at 6 and 12 weeks of the intervention and at 24 weeks 
(12 weeks after cessation of the intervention).  
Vascular assessments – Ultrasound assessments of the right brachial artery were performed 
while the participant rested supine. All assessments were undertaken by one researcher 
(coefficient of variation for repeated FMD measures 10.97%) using a 7-mHz linear array 
transducer attached to a high-frequency ultrasound system (Terason T3000, Teratech 
Corporation, Burlington, MA, USA). Participants rested quietly for a minimum of 15 minutes 
prior to commencing assessments. 
For FMD assessments, a pneumatic rapid inflation/deflation cuff (Hokanson E20 cuff, D.E. 
Hokanson Inc, Bellevue, WA, USA) was placed distal to the olecranon process, with arterial 
imaging performed in the distal third of the upper arm. Resting measurement of vessel 
diameter was performed for one minute prior to cuff inflation to a pressure 50 mmHg above 
systolic blood pressure. Occlusion was maintained for five minutes. Recordings were 
restarted 30 s before cuff release and continued for a further three minutes thereafter [Black 
et al, 2008]. 
After 15 minutes rest following FMD assessments, GTN-mediated brachial artery dilatation 
was assessed. Arterial imaging was performed for 1 minute before administration of a 
sublingual dose (0.4 mg) of GTN, and continued for a further six minutes thereafter [Corretti 
et al, 2002] with recording maintained throughout. 
The ultrasound on-screen display was recorded at a rate of 15 Hz (Camtasia Studio software, 
v5.0.0, TechSmith Corporation, Okemos, MI, USA). Subsequently analysis was undertaken 
using the Brachial Analyser for Research software package (v5.6.19, Medical Imaging 
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Applications, Iowa, USA). All scans were analysed in full by a researcher external to the 
research team who was blinded to participant group allocation.  
Raw data for arterial diameter were smoothed prior to determination of the magnitude of 
arterial dilatation using the same method as previously described [Black et al, 2008]. Arterial 
data are displayed as the absolute (millimetres) and relative (percentage) change in arterial 
diameter from resting arterial diameter (Drest) to peak arterial diameter (Dpeak). For analysis, 
data were allometrically scaled [Atkinson et al, 2013]. Arterial shear rate (SR) for FMD 
assessments was calculated using the equation SR = 4*V/D, where V is Doppler velocity 
and D is vessel diameter [Parker et al, 2009]. SR area under the curve (SR AUC) was 
calculated as the sum of arterial shear from cuff release through to Dpeak. 
Anthropometry - Stature (Holtain Stadiometer, Holtain Ltd, Pembrokeshire, UK) and body 
mass (Weylux Beam Balance Scales, Weylux, UK) were assessed using standard laboratory 
techniques to 0.1 cm and 0.05 kg respectively, and body mass index (BMI) was calculated. 
Body composition was assessed via bioelectrical impedance (Inbody 720, Biospace, Seoul, 
South Korea).  
Resting blood pressure - Resting blood pressure and heart rate were assessed in the left 
arm with an automated sphygmomanometer (Dinamap, Dash 2500, GE Healthcare, 
Waukesha, WI, USA) while participants rested supine before FMD assessments. 
Exercise tolerance – A sub-maximal walking test was performed on a treadmill (H/P/ 
Cosmos Pulsar Treadmill, Traunstein, Germany) using the BSU/Bruce protocol [Kaminsky 
and Whaley, 1998]. Participants were given time walking on a treadmill before the test to 
allow them to become comfortable with treadmill use. A chest-strap heart rate monitor (Polar 
F4, Polar Electro, Kempele, Finland) was fitted and participants were accustomed to the 6-
20 Borg scale [Borg, 1982]. Heart rate and RPE were recorded at the end of every minute of 
exercise. The test ended when participants achieved an RPE of 15 (‘Hard’) or earlier if the 
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participant requested to stop. Treadmill tests were conducted by a researcher external to the 
research team who was blinded to participant group allocation. 
Blood markers - A fasting blood sample (20 ml) was drawn from the antecubital vein using 
standard venepuncture techniques. Samples were analysed in duplicate in the Department 
of Clinical Chemistry at the Royal Hallamshire Hospital, Sheffield, UK for blood lipid profile 
(total cholesterol, HDL-C, LDL-C and triglycerides), prostate-specific antigen and male sex 
hormones (testosterone, SHBG). In addition, free androgen index was calculated.  
Exercise and dietary behaviour - Leisure time physical activity was quantified using the 
Godin Leisure Score Index (Godin LSI) [Godin and Shephard, 1985]. A higher score 
indicated more activity. The Godin LSI has been successfully used with men on ADT [Culos-
Reed et al, 2010].  
Participants completed 3-day diet diaries at baseline, 12 and 24 weeks. Where possible, 
participants were asked to use the same three days of the week for each assessment. 
Nutritional data was analysed using NetWisp (version 3.0, Tinuviel Software, Anglesey, UK).   
STATISTICAL ANALYSIS 
Analyses were performed in Stata v13 on an intention-to-treat basis including all available 
participants in the groups to which they were randomised, using two-sided significance at the 
5% level. Treatment effects are presented as the difference in adjusted means (intervention 
minus control) and Hedge’s g effect sizes with 95% confidence intervals (CI) and p-values.   
Arterial diameter data (FMD and GTN-mediated dilation) were allometrically-scaled and 
analysed as follows. The difference between logarithmically transformed Drest and Dpeak was 
calculated for each participant and time-point and then analysed using a covariance pattern 
mixed model, with treatment group, time and a treatment group-by-time interaction as fixed 
factors, and log Drest as a time-varying covariate. Means for diameter change on the logged 
scale for each treatment group and time point were obtained and then back-transformed by 
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antilogging to provide an adjusted ratio of Dpeak/Drest, subtracting a value of 1 and multiplying 
by 100 to provide a Drest adjusted estimate of relative FMD.  An estimate for the standard 
deviation was obtained by multiplying the standard error of the mean diameter change by the 
square root of the sample size, antilogging, subtracting 1 and multiplying by 100.  Estimates 
for the difference in mean diameter change between the treatment groups at each time point 
were extracted from the model with 95% confidence intervals and p-values. The p-values are 
presented unchanged in this paper, but the point and interval estimates were transformed as 
described above. 
To allow comparison of the results with previous publications using a simple ratio only, the 
difference in (simple ratio) relative FMD between the trial arms at 12 weeks was extracted 
from a single linear covariance pattern mixed model in which relative FMD at each time point 
was nested within patients [Brown and Prescott, 2006]. Relative FMD at baseline, each time 
point of follow-up, trial arm and a time-by-trial arm interaction were included in the model. 
The estimates of the treatment effect at 6 and 24 weeks were extracted for secondary 
investigations. Estimation was based on the method of restricted maximum likelihood 
[Harville, 1977].   
The following outcomes were analysed in the same way as (simple ratio) relative FMD: 
absolute FMD, relative GTN dilation, absolute GTN dilation, systolic and diastolic blood 
pressure, BMI and treadmill walk time.  
All other secondary outcomes were compared between the treatment groups at 12 weeks 
using ANCOVA to adjust for the baseline value. No adjustment for multiple testing was made. 
RESULTS  
This analysis is of 50 men (mean age 70 years – range 53 to 84 years) consecutively 
recruited to the latter part of the primary trial [Bourke et al, 2014] with 25 randomised to each 
trial arm (Figure 1). The median time on ADT at recruitment was 19 and 18 months in the 
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intervention and control groups respectively. The groups were comparable at baseline with 
the exception of previous radiotherapy exposure (Table 1).  
There were seven withdrawals (three in the intervention and four in the control group) and 
one death (control group) before the end of the 12-week intervention. There was one 
additional withdrawal and death (both intervention group) prior to the 24 week assessment. 
Both deaths were considered unrelated to the study intervention. For men completing the 12 
week intervention, adherence to supervised sessions was 93% (368 of 396 possible) and to 
and home-based sessions was 76% (301 of 396 completed) respectively.  
At 12 weeks the difference in allometrically-scaled relative FMD was 2.2% (95% CI 0.1 to 4.3, 
p=0.04, Hedge’s g 0.60, 95% CI <0.01 to 1.18) favouring the intervention group (Table 2).   
The difference in absolute FMD was 0.11 mm (95% CI <0.01 to 0.23, p=0.05, Hedge’s g 
0.59, 95% CI -0.01 to 1.17). This benefit was not maintained at 24 weeks (0.31 SD, 95% CI -
0.27 to 0.88 for allometrically-scaled relative FMD and 0.31 SD, 95% CI -0.27 to 0.89 for 
absolute FMD). The results for the non-scaled simple ratio FMD are presented alongside the 
scaled results in Table 2.  
There was no meaningful difference in GTN dilation (absolute or relative), systolic and 
diastolic blood pressure values or BMI at any post-randomisation time point (Table 2).  
Treadmill walk time improved in the intervention group. The difference at 12 and 24 weeks 
was 88 seconds (95% CI 52 to 123, p<0.001, Hedges g 1.41, 95% CI 0.76 to 2.05) and 69 
seconds (95% CI 33 to 105, p<0.001), respectively (Table 2).  
Exercise behaviour scores from the Godin LSI were improved in the intervention group at all 
follow-up time points during the intervention with statistically significant differences at 6 and 
12 weeks (6 weeks p=0.02; 12 weeks p=0.05). At 12 weeks, there was a moderate 
beneficial effect of the intervention of 0.57 SD (95% CI -0.02 to 1.15). There was no 
difference detected in exercise behaviour at 24 weeks (p=0.58).   
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There were improvements in Dpeak for the FMD test, skeletal muscle mass (Table 3) and 
SHBG (Table 4) at 12 weeks. No meaningful change occurred in any other physiological 
measure or in any dietary outcomes.  
DISCUSSION 
At the end of the exercise intervention (12 weeks) a beneficial effect of the intervention on 
endothelial function occurred with an increased relative FMD of 2.2% (effect size of >0.5 SD). 
These differences between groups were not maintained 12 weeks after withdrawal of the 
intervention. 
There is academic debate around how best to report relative FMD, with much of the earlier 
work using a simple ratio. Problems with these ratios have been identified [Tanner, 1949] 
and allometric scaling of ratio data for physiological measurements has been shown to be a 
more appropriate form of data analysis and presentation [Curran-Everett, 2013, Packard and 
Boardman, 1999]. Such scaling more accurately accounts for variability in body and other 
anatomical sizes. Recently Atkinson [2014] confirmed the appropriateness of allometric 
scaling for changes in arterial diameter in FMD analysis. In the current study, without such 
scaling, the difference in relative FMD expressed as a simple ratio is almost identical in 
magnitude (2.3%) to the allometric-scaled value with a similar effect size (table 2).   
FMD has been widely associated with changes in cardiovascular health.  An inverse 
relationship between relative FMD and the risk of future cardiovascular events (e.g. 
myocardial infarction, stroke) exists, with a metaanalysis suggesting reduced cardiovascular 
risk of 13% (95% CI 8 to 17%) per 1% higher relative FMD in individuals with any pre-
existing cardiovascular risk factor [Ras et al, 2013]. Although these findings have been 
developed from non-scaled data, reanalysis of the Multi Ethnic Study of Atherosclerosis 
indicated that allometric-scaled FMD is robust in the association with cardiovascular health 
outcomes [Atkinson and Batterham, 2013]. Within the current study, 68% of the men had 
pre-existing evidence of cardiovascular disease (table 1), but a diagnosis of prostate cancer 
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in itself appears to be associated with increased cardiovascular risk: a comprehensive 
registry-based study from Sweden found that men diagnosed with prostate cancer appear to 
constitute a particularly high-risk group for cardiovascular events over matched-controls 
without cancer, with treatment by ADT conferring additional risk [Van Hemelrijck et al, 2010]. 
An estimated annual cardiovascular event rate of approximately 14.2% in the Swedish 
PCBaSe study referred to above was reported in a recent meta-analysis [Bosco et al, 2015]. 
Extrapolating from these data, one can tentatively estimate that, were the changes in FMD 
seen in this study translated to clinically significant risk reduction, 29% fewer cardiovascular 
events would be encountered, providing an absolute risk reduction of 4.1%. Otherwise 
stated, one would have to deliver the intervention to 24 men to prevent a single 
cardiovascular event per annum. As such, the results of the current study are suggestive of 
cardiovascular benefit of a 12 week exercise intervention in men on ADT, although further 
studies are required to correlate changes with cardiovascular outcomes. 
Several mechanisms could be responsible for the changes observed in FMD. Previous 
studies have demonstrated improvements in endothelial function with increased physical 
activity are only partly mediated by changes in traditional cardiovascular risk factors [Green 
et al, 2003]. A direct effect of periods of increased shear stress on arterial walls during 
exercise can lead to increased nitric-oxide dependent vascular dilation [Tinken et al, 2010]. 
Such an explanation could account for the observed changes in FMD, despite only small 
effects on other cardiovascular risk factors. Changes in SHBG at 12 weeks could be 
indicative of changes in insulin resistance between groups [Wallace et al, 2013], which could 
influence FMD [Suzuki et al, 2004]. Although SHBG has been shown to increase after 
lifestyle interventions including exercise and diet in healthy adult males [Tymchuk et al, 1998]         
consistent with changes in insulin concentrations, the results of the current study could be 
interpreted as a deterioration in insulin sensitivity in the control group leading to a reduction 
in SHBG given the association between long-term ADT and increasing risk of developing 
14 
 
type II diabetes [Alibhai et al, 2009]. However, given the small sample size of the study, such 
an interpretation should be made with caution. 
Previous evidence of improvements in cardiovascular health with exercise training in men 
established on ADT is limited. Recent studies have shown improvements in anthropometric 
and metabolic markers of cardiovascular risk with exercise training [Cormie et al, 2015, 
Nobes et al, 2012], however in both studies participants started the intervention at the same 
time as commencing ADT and so whether such results could be achieved in men on long-
term ADT remained unclear. Reductions in systolic and diastolic blood pressure were 
reported by Culos-Reed et al., [2010] in men on long-term ADT who underwent a 16 week 
programme of home-based exercise, however changes of a similar magnitude were also 
found in a non-exercising control group, resulting in no difference between groups over time. 
More positively, Galvao et al., [2010] reported decreased concentrations of C-reactive 
protein after a 12 week supervised exercise intervention, but this finding was not supported 
by evidence of benefits in any other markers of cardiovascular health. As such, our finding of 
an improvement in endothelial function provides the most encouraging evidence of 
cardiovascular benefits following a lifestyle intervention in men on long-term ADT. 
Statistically significant changes in skeletal muscle were observed over the duration of the 
intervention. These findings support evidence that lifestyle interventions can reverse the 
decrease in lean body mass experienced by men treated with ADT [Galvao et al, 2010, 
Galvão et al, 2014]. The largest effect of the intervention was seen in treadmill walk time 
however. Although improvements from baseline walking distance was seen in the control 
group this did not match the magnitude of improvements in the intervention group. This 
evidence demonstrates exercise training can reduce the decline in physical function 
observed with ADT [Alibhai et al, 2010]. 
Evidence of an increase in exercise behaviour and exercise tolerance in the control group is 
one limitation of the current study. Although similar changes in exercise behaviour have 
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previously been reported in cancer patients randomised to a control group of an exercise 
study [Courneya et al, 2004], such findings could have a confounding effect on overall 
conclusions. 
A further limitation of this study is that improvements in a number of outcome measures 
seen at end-point assessments in the intervention group were lost following withdrawal of 
supervision. Conducting follow-up assessments after a lifestyle intervention has previously 
been undertaken by one study which reported a similar pattern of changes [Bourke et al, 
2011]. Designing effective lifestyle interventions for this population that can maintain benefits 
after removal of supervision is clearly an area in which further investigations are warranted. 
Finally, the controlled recruitment of men into this study could limit generalisability of the 
findings. As part of the first study to report an exercise-based intervention in men with 
metastatic prostate cancer [Bourke et al, 2014, Bourke et al, 2011], the necessity to maintain 
rigour and ensure patient safety resulted in the exclusion of 67% of men identified as being 
treated with ADT. Comparison of this exclusion rate against other studies is difficult due to 
variations in the detail of recruitment statistics reported, however the study establishes the 
principle that such lifestyle interventions are feasible in this population, an important 
consideration for future studies. 
In conclusion, our findings demonstrate evidence of improvements in endothelial function 
after a lifestyle intervention including supervised exercise training and dietary advice in men 
on long-term ADT for prostate cancer which were not maintained following withdrawal of the 
intervention. Larger studies are required to investigate any impact on clinically relevant 
cardiovascular outcomes, as well as the value of a longer supervised intervention. 
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Followed-up at 6 weeks (n=24) 
Followed-up at 24 weeks (n=20) 
Followed-up at 12 weeks (n=22) 
Lost to follow-up (n=2) 
Died (n=1) 
Lost to follow-up (n=1) 
 
Followed-up at 6 weeks (n=21) 
Followed-up at 12 weeks (n=20) 
Followed-up at 24 weeks (n=20) 
Lost to follow-up (n=1) 
Allocated to Intervention (n=25) Allocated to Usual Care (n=25) 
Lost to follow-up (n=3) 
Died (n=1) 
Men identified as on ADT from clinic lists (n=831) 
Full details available for screening (n=778) 
Excluded at screening (n=514): 
Progressive disease (rising PSA/painful metastases) (n=174) 
Comorbidities (n=110) 
Less than 6 months of ADT and/or less than 12 since EBRT 
(n=98) 
Physical impairment making participation unsuitable (n=50) 
Participating in another study (n=35) 
Active treatment for another cancer (n=26) 
Due to stop ADT in < 6 months (n=15) 
Language barrier (n=4) 
Previously stated no interest in clinical trials (n=2) 
Suitable to approach (n=263) 
Attended familiarisation (n=53) 
Not interested in participating 
(n=26): 
Insufficient time to participate (n=8) 
Not interested in the trial (n=7) 
Already do regular exercise (n=6) 
Other work/caring commitments (n=5) 
Travel constraints (n=3) 
Sent a letter (n=183) 
Expressed interest in participating (n=44) 
Approached in clinic (n=80) 
Expressed interest in participating (n=51) 
No reply (n=69) 
Not interested (n=70) 
 
Withdrew interest (n=41) 
Couldn’t be contacted (n=1) 
Consented to participate and randomised (n=50) 
Excluded: 
Had health issues that had not been identified from 
patient notes (n=3). 
Lost to follow-up (n=1) 
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Table 1. Baseline characteristics of the participants by treatment group  
Characteristic 
Intervention 
(n=25) 
Control 
(n=25) 
Total 
(n=50) 
Age, years 
Mean (SD) 
(Min, max) 
N=25 
70.1 (5.3) 
       (57, 80) 
N=25 
70.4 (9.2)         
(53, 84) 
N=50 
70.2 (7.4)       
(53, 84) 
Ethnicity, n (%) 
White 
Asian 
Black 
N=25 
25 (100) 
0 (0) 
0 (0) 
N=25 
22 (88) 
2 (8) 
1 (4) 
N=50 
47 (94) 
2 (4) 
1 (2) 
In employment, n(%) 
N=25 
4 (16) 
N=25 
5 (20) 
N=50 
9 (18) 
Smoking status, n(%) 
Current smoker 
Previous smoker 
N=25 
1 (4) 
12 (48) 
N=25 
0 (0) 
11 (44) 
N=50 
1 (2) 
23 (46) 
Treatment details, n(%) 
LHRH* agonist alone 
MAB* 
N=25 
25 (100)  
0 (0) 
N=25 
23 (92) 
2 (8) 
N=50 
48 (96) 
2 (4) 
Time on ADT*, months 
Median (IQR) 
(Min, max) 
N=25 
19 (12, 36) 
(6, 138) 
N=25 
18 (9, 25) 
(6, 92) 
N=50 
19 (9, 36) 
(6, 138) 
Previous EBRT*, n(%) 
N=25 
13 (52) 
N=25 
7 (28) 
N=50 
20 (40) 
Time since EBRT, months 
Median (IQR) 
(Min, max) 
N=12 
17 (12, 28) 
(12, 95) 
N=7 
20 (14, 58) 
(12, 130) 
N=19 
18 (12, 33) 
        (12, 130) 
Previous radical 
prostatectomy, n(%) 
N=25 
1 (4) 
N=25 
3 (12) 
N=50 
4 (8) 
Medical history and 
comorbidities, n(%) 
Previous MI* 
Previous stroke 
Angina 
Diabetes 
Hypertension 
Hypertension diagnosed since 
ADT commencement 
 
N=25 
2 (8) 
0 (0) 
3 (12) 
3 (12) 
16 (64)  
 
3 (12) 
 
N=25 
2 (8) 
2 (8) 
2 (8) 
4 (16) 
11 (44) 
 
2 (8) 
 
N=50 
4 (8) 
3 (6) 
5 (10) 
7 (14) 
27 (54) 
 
5 (10) 
Medication, n(%) 
Statin therapy 
Beta blockers 
Calcium channel blockers 
ACE inhibitors 
Diuretics 
Angiotensin-II inhibitors 
Prostaglandin analogues 
Anti-coagulant therapy 
Anti-diabetic medication 
N=25 
14 (56) 
8 (32) 
12 (48) 
9 (36) 
4 (16) 
3 (12) 
7 (28) 
2 (8) 
3 (12) 
N=25 
13 (52) 
6 (24) 
4 (16) 
8 (32) 
6 (24) 
3 (12) 
6 (24) 
1 (4) 
3 (12) 
N=50 
27 (54) 
14 (28) 
16 (32) 
17 (34) 
10 (20) 
6 (12) 
13 (26) 
3 (6) 
6 (12) 
*LHRH = Luteinizing hormone-releasing hormone; MAB= Maximum androgen blockade; ADT = 
Androgen deprivation therapy; EBRT = External beam radiotherapy; MI = Myocardial Infarction 
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Table 2. Summary of outcome measures by treatment group 
Outcome 
 
Intervention  
(n=25) 
Raw mean (SD) 
Control  
(n=25) 
Raw mean (SD) 
Adjusted mean 
difference at 12 weeks 
(95% CI) 
p-value 
Effect size in SD  
(95% CI) 
Allometrically 
scaled relative 
FMD (%)* 
Baseline 
Week 6 
Week 12 
Week 24 
4.5 (3.4) 
6.9 (3.4) 
7.6 (3.4) 
7.5 (3.4) 
4.6 (3.4) 
4.4 (3.4) 
5.3 (3.4) 
6.3 (3.4) 
2.2 (0.1, 4.3)  
p=0.04 
0.60 (0.005, 1.18) 
Non-scaled 
relative FMD (%)* 
Baseline 
Week 6 
Week 12 
Week 24 
4.6 (4.2) 
7.0 (3.9) 
7.7 (4.1) 
7.5 (4.0) 
4.7 (4.2) 
4.5 (3.8) 
5.3 (4.0) 
6.3 (4.0) 
2.3 (0.1, 4.5) 
p=0.04 
0.60 (0.01, 1.19) 
Absolute FMD 
(mm) 
Baseline 
Week 6 
Week 12 
Week 24 
0.23 (0.18) 
0.35 (0.22) 
0.37 (0.20) 
0.37 (0.18) 
0.22 (0.11) 
0.23 (0.20) 
0.25 (0.15) 
0.30 (0.16) 
0.11 (0.00, 0.23) 
p=0.05 
0.59 (-0.01, 1.17) 
Allometrically 
scaled GTN-
mediated dilation 
(%)* 
Baseline 
Week 6 
Week 12 
Week 24 
12.3 (4.2) 
11.2 (4.2) 
11.5 (4.2) 
13.4 (4.2) 
11.9 (4.2) 
14.6 (4.2) 
10.9 (4.2) 
11.3 (4.2) 
0.6 (-2.4, 3.6) 
p=0.71 
0.11 (-0.47, 0.68) 
Non-scaled 
relative GTN-
mediated dilation 
(%) 
Baseline 
Week 6 
Week 12 
Week 24 
12.5 (5.0) 
12.0 (3.5) 
12.2 (5.5) 
13.9 (4.5) 
12.0 (4.3) 
14.6 (6.3) 
10.4 (4.5) 
11.0 (4.9) 
1.2 (-2.2, 4.7) 
p=0.48 
0.21 (-0.37, 0.78) 
Absolute GTN-
mediated dilation 
(mm) 
Baseline 
Week 6 
Week 12 
Week 24 
0.62 (0.25) 
0.57 (0.15) 
0.58 (0.27) 
0.67, (0.22) 
0.59 (0.20) 
0.74 (0.31) 
0.52 (0.21) 
0.55 (0.24) 
0.04 (-0.13, 0.20) 
p=0.66 
0.13 (-0.45, 0.70) 
Systolic blood 
pressure (mmHg) 
Baseline 
Week 6 
Week 12 
Week 24 
144 (18)      
137 (14) 
138 (20) 
139 (19) 
145 (20)      
147 (19) 
145 (20) 
141 (23) 
-7.0 (-16.1, 2.2) 
p=0.14 
0.44 (-0.15, 1.02) 
Diastolic blood 
pressure (mmHg) 
Baseline 
Week 6 
Week 12 
Week 24 
80 (8) 
77 (9) 
76 (10) 
77 (11) 
76 (8) 
76 (7) 
76 (7) 
75 (8) 
-3.3 (-7.0, 0.4)  
p=0.08 
0.50 (-0.09, 1.08) 
BMI (kg/m2) 
Baseline 
Week 6 
Week 12 
Week 24 
30.6 (5.0) 
30.3 (5.0) 
29.8 (4.8) 
28.9 (2.8) 
28.8 (5.2) 
28.4 (3.2) 
29.0 (4.8) 
29.0 (4.8) 
0.1 (-0.5, 0.6) 
p=0.74 
-0.10 (-0.67, 0.48) 
Treadmill walk 
time (seconds) 
Baseline 
Week 6 
Week 12 
Week 24 
344 (144)       
420 (143) 
435 (133) 
447 (131) 
346 (162)        
411 (134) 
389 (115) 
400 (121) 
87.6 (52.0, 123.3) 
p<0.001 
1.41 (0.76, 2.05) 
Godin LSI 
Baseline 
Week 6 
Week 12 
Week 24 
20.5 (13.2) 
31.0 (17.8) 
38.4 (27.2) 
36.5 (27.5) 
20.7 (17.3) 
22.4 (22.0) 
26.2 (21.1) 
31.4 (30.4) 
12.5 (-0.1, 25.0) 
p=0.05 
0.57 (-0.02, 1.15) 
*adjusted “corrected” mean relative dilation; FMD = Flow-mediated dilation; GTN = Glyceryl trinitrate; BMI = Body 
mass index; Godin LSI = Godin leisure score index 
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Figure 2. Allometrically-scaled, adjusted mean relative FMD by treatment group at all time 
points, with 95% confidence intervals and p-values 
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Table 3. Summary of secondary outcome measures by treatment group 
Outcome 
Intervention  
(n=25) 
Raw mean (SD) 
Control  
(n=25) 
Raw mean (SD) 
Adjusted mean 
difference at 12 weeks 
(95% CI) 
p-value 
FMD Drest (mm) 
Baseline 
Week 6 
Week 12 
Week 24 
4.9 (0.6)  
5.0 (0.8) 
5.0 (0.5) 
4.9 (0.6) 
4.8 (0.5) 
5.0 (0.6)  
4.8 (0.5) 
4.8 (0.6) 
0.1 (-0.1, 0.3) 
p=0.27 
FMD Dpeak (mm) 
Baseline 
Week 6 
Week 12 
Week 24 
5.1 (0.7) 
5.3 (0.9) 
5.3 (0.5) 
5.3 (0.6) 
5.0 (0.6) 
5.2 (0.7) 
5.1 (0.5) 
5.1 (0.6) 
0.2 (0.0, 0.5) 
p=0.04 
GTN Drest (mm) 
Baseline 
Week 6 
Week 12 
Week 24 
5.0 (0.5)      
4.8 (0.6) 
4.9 (0.5) 
4.9 (0.4) 
5.0 (0.6)       
5.2 (0.6) 
5.2 (0.6) 
5.1 (0.6) 
-0.2 (-0.6, 0.1) 
p=0.12 
GTN Dpeak (mm) 
Baseline 
Week 6 
Week 12 
Week 24 
5.6 (0.6)     
5.4 (0.6) 
5.5 (0.6) 
5.6 (0.5) 
5.6 (0.7)      
5.9 (0.6) 
5.7 (0.6) 
5.6 (0.6) 
-0.2 (-0.6, 0.1) 
p=0.18 
Body fat mass 
(kg) 
Baseline 
Week 6 
Week 12 
Week 24 
34.5 (11.6) 
32.9 (11.2) 
31.6 (10.9) 
29.9 (7.1) 
30.4 (11.5) 
27.9 (7.4) 
29.6 (10.9) 
29.0 (11.1) 
-0.7 (-2.2, 0.7) 
p=0.32 
Skeletal 
muscle mass 
(kg) 
Baseline 
Week 6 
Week 12 
Week 24 
31.9 (4.2) 
32.3 (4.6) 
32.9 (4.6) 
32.7 (4.0) 
31.2 (5.7) 
31.6 (6.0) 
32.3 (5.5) 
32.6 (5.7) 
0.6 (0.1, 1.1) 
p=0.03 
FMD = Flow-mediated dilation; Drest = Resting arterial diameter; Dpeak = Peak arterial diameter; SR AUC = Shear rate 
area under the curve; GTN = Glyceryl trinitrate 
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Table 4. Summary of lipid profile and blood marker measures by treatment group 
Outcome 
Intervention  
(n=25) 
Raw mean (SD) 
Control  
(n=25) 
Raw mean (SD) 
Adjusted mean 
difference at 12 weeks 
(95% CI) 
p-value 
Lipid profile     
Total cholesterol 
(mmol.L) 
Baseline 
Week 12 
5.0 (1.2) 
4.9 (1.1) 
4.7 (0.9) 
4.8 (0.8) 
-0.0 (-0.3, 0.3) 
p=0.83 
HDL-C (mmol.L) 
Baseline 
Week 12 
1.4 (0.4) 
1.4 (0.4) 
1.5 (0.5) 
1.5 (0.5) 
0.0 (-0.1, 0.1) 
p=0.60 
LDL-C (mmol.L) 
Baseline 
Week 12 
2.7 (1.1) 
2.8 (1.0) 
2.4 (0.8) 
2.6 (0.8) 
-0.0 (-0.3, 0.2) 
p=0.79 
Triglycerides 
(mmol.L) 
Baseline 
Week 12 
1.9 (0.7) 
1.6 (0.7) 
1.7 (1.0) 
1.6 (0.8) 
-0.1 (-0.3, 0.2) 
p=0.51 
Blood markers     
Total testosterone 
(nmol.L) 
Baseline 
Week 12 
0.5 (0.2) 
0.4 (0.1) 
0.5 (0.2) 
0.4 (0.2) 
-0.0 (-0.1, 0.0) 
p=0.43 
SHBG (nmol.L) 
Baseline 
Week 12 
54.0 (33.0) 
54.6 (23.8) 
56.9 (31.6) 
51.0 (30.2) 
5.8 (0.8, 10.9) 
p=0.03 
Free androgen 
index 
Baseline 
Week 12 
1.2 (0.8) 
1.0 (0.5) 
1.2 (1.0) 
1.3 (1.1) 
-0.2 (-0.5, 0.1) 
p=0.17 
Prostate-specific 
antigen (ng.ml) 
Baseline 
Week 12 
2.1 (4.8) 
3.7 (8.7) 
1.5 (2.7) 
2.3 (4.5) 
0.1. (-1.0, 1.3) 
p=0.80 
HDL-C = High-density lipoprotein-cholesterol; LDL-C = Low-density lipoprotein-cholesterol; SHBG = Sex-hormone 
binding globulin 
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Supplementary table 1. Summary of daily nutrient intake by treatment group 
Outcome 
Intervention  
(n=25) 
Control  
(n=25) 
Adjusted mean 
difference at 12 
weeks (95% CI) 
p-value 
Total energy 
(kcalories) 
Baseline 
Week 12 
Week 24 
1943.9 (487.3) 
1869.7 (392.1) 
2080.6 (498.1) 
2083.8 (542.0) 
1930.6 (554.4) 
1942.4 (539.6) 
34.5 (-282.3, 351.4) 
p=0.83 
Total fat (grams) 
Baseline 
Week 12 
Week 24 
75.0 (31.1) 
72.3 (22.3) 
79.2 (27.2) 
78.1 (28.7) 
72.0 (25.6) 
77.8 (37.2) 
6.1 (-10.4, 22.6) 
p=0.45 
Saturated fat 
(grams) 
Baseline 
Week 12 
Week 24 
25.6 (12.0) 
25.4 (7.4) 
28.4 (8.8) 
28.2 (11.1) 
26.8 (9.7) 
27.5 (11.8) 
0.6 (-5.4, 6.6) 
p=0.84 
Monounsaturated 
fat (grams) 
Baseline 
Week 12 
Week 24 
22.0 (9.3) 
22.5 (8.2) 
25.5 (10.0) 
24.3 (10.1) 
22.6 (9.1) 
24.4 (9.9) 
2.3 (-3.5, 8.1) 
p=0.43 
Polyunsaturated 
fat (grams) 
Baseline 
Week 12 
Week 24 
10.3 (4.5) 
10.6 (5.0) 
12.0 (6.2) 
11.0 (5.2) 
11.2 (6.3) 
11.4 (4.7) 
0.8 (-3.0, 4.5) 
p=0.67 
Carbohydrate 
(grams) 
Baseline 
Week 12 
Week 24 
226.4 (51.8) 
220.1 (51.5) 
258.9 (113.5) 
266.1 (101.2) 
245.9 (77.5) 
230.1 (50.5) 
-12.8 (-59.5, 33.8) 
p=0.58 
Protein  
(grams) 
Baseline 
Week 12 
Week 24 
80.7 (28.6) 
79.7 (20.0) 
81.7 (19.4) 
81.0 (20.1) 
80.5 (25.4) 
80.3 (17.7) 
3.5 (-11.5, 18.6) 
p=0.64 
Cholesterol  
(mg) 
Baseline 
Week 12 
Week 24 
263.4 (118.4) 
279.2 (91.8) 
274.8 (96.0) 
248.7 (98.8) 
245.1 (115.1) 
274.1 (151.1) 
52.7 (-29.7, 135.1) 
p=0.20 
Sugars 
(grams)  
Baseline 
Week 12 
Week 24 
104.8 (39.9) 
101.0 (35.1) 
139.7 (109.3) 
131.9 (96.6) 
117.0 (67.3) 
104.6 (33.3) 
-6.3 (-43.4, 30.9) 
p=0.73 
Starch  
(grams) 
Baseline 
Week 12 
Week 24 
119.2 (27.2) 
115.6 (31.3) 
116.3 (31.4) 
131.8 (34.9) 
126.0 (31.9) 
123.0 (36.3) 
-9.4 (-33.5, 14.6) 
p=0.43 
Fibre (grams) 
Baseline 
Week 12 
Week 24 
16.0 (4.8) 
14.8 (3.5) 
14.4 (3.8) 
14.9 (3.7) 
14.8 (4.5) 
16.1 (4.1) 
0.6 (-1.8, 3.0) 
p=0.60 
Vitamin E  
(mg) 
Baseline 
Week 12 
Week 24 
7.2 (3.1) 
6.4 (2.3) 
7.2 (3.4) 
6.9 (2.1) 
6.6 (4.1) 
7.3 (2.6) 
0.6 (-1.5, 2.7) 
p=0.57 
Vitamin C  
(mg) 
Baseline 
Week 12 
Week 24 
113.1 (70.8) 
119.1 (58.5) 
113.1 (53.3) 
111.5 (76.3) 
94.5 (50.7) 
113.0 (31.9) 
34.9 (-2.5, 72.3) 
p=0.07 
Alcohol 
(grams)  
Baseline 
Week 12 
Week 24 
14.4 (15.0) 
11.3 (11.9) 
10.6 (7.4) 
8.9 (10.1) 
6.0 (9.0) 
8.8 (12.1) 
4.6 (-3.3, 12.5) 
p=0.24 
 
